ClinicalTrials.gg
CompletedNCT06194500Updated Mar 28, 2024

A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants

A Phase 1 interventional study of [14C]-LY3549492 and LY3549492 in Healthy Male, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to male participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
35 Years to 65 Years
Sex
Male
01

Study summary

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will be conducted in healthy males and has two parts. In Part A, participants will receive carbon-14 (14C) radiolabeled LY3549492 ([14C] LY3549492) given by mouth. In Part B, participants will receive LY3549492 by mouth. Three hours later, participants will receive [14C] LY3549492 given into a vein.

The radioactive substance C14 will be incorporated into the study drug to investigate the study drug and breakdown products to find out how much of these passes from blood into urine, stool, and breath.

The study will last about 2 months in Part A and about 1½ months in Part B. This includes screening, treatment, and follow-up visits.

02

Conditions studied

  • Healthy Male
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and (ECG).
  • Participants who have safety laboratory test results within normal reference ranges, or results with acceptable deviations that are deemed not by the investigator.
  • (BMI) within the range of 20.0 to 40.0 kilograms per meter squared (kg/m2), inclusive.
  • use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to LY3549492, glucagon-like peptide-1 (GLP-1) non-peptide agonist (NPA)-related compounds or any components of the formulation as appropriate, or history of atopy.
  • Have a clinical diagnosis of a long syndrome.
  • Have any abnormality in the 12-lead at screening that, in the opinion of the investigator, may increase the risk associated with participation in the study or may confound ECG data analysis.
  • Have significant history of any current serious medical condition.
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or have an elevation in serum amylase or lipase (>1.0×Upper Limit Normal ()).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Carbon-14-Labeled [14C]-LY3549492 - Part A

    Carbon-14-Labeled \[14C\]-LY3549492 administered as oral solution.

    Drug: [14C]-LY3549492

  • Experimental
    LY3549492 + [14C]-LY3549492 - Part B

    LY3549492 administered as oral solution followed 3 hours later by \[14C\] LY3549492 will be administered as intravenous (IV) infusion.

    Drug: LY3549492 · Drug: [14C]-LY3549492

Interventions

06

What researchers measure

Primary outcomes

  1. Urinary Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part A

    Urinary Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose

    Time frame: Predose up to Day 24 postdose in Part A

  2. Fecal Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part A

    Fecal Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total

    Time frame: Predose up to Day 24 postdose in Part A

  3. Pharmacokinetic (PK): Area Under the Curve (AUC) for Oral Determination of Absolute Bioavailability (F) of LY3549492 in Part B

    PK: AUC for oral determination of absolute bioavailability (F) of LY3549492

    Time frame: Predose up to Day 7 postdose in Part B

  4. PK: AUC for Intravenous (IV) Determination of Absolute Bioavailability (F) of LY3549492 in Part B

    PK: AUC for IV determination of absolute bioavailability (F) of LY3549492

    Time frame: Predose up to Day 7 postdose in Part B

Secondary outcomes

  1. PK: Area Under the Concentration (AUC) for Radioactivity in Plasma and Whole Blood in Part A

    PK: AUC for radioactivity

    Time frame: Predose up to Day 24 postdose in Part A

  2. PK: Maximum Concentration (Cmax) for Radioactivity in Plasma and Whole Blood in Part A

    PK: Cmax for radioactivity

    Time frame: Predose up to Day 24 postdose in Part A

  3. PK: AUC of LY3549492 in Plasma in Part A

    PK: AUC of LY3549492 in plasma

    Time frame: Predose up to Day 24 postdose in Part A

  4. PK: Cmax of LY3549492 in Plasma in Part A

    PK: Cmax of LY3549492 in plasma

    Time frame: Predose up to Day 24 postdose in Part A

  5. Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable) in Part A

    Total radioactivity recovered in urine, feces, and expired air (if applicable) in Part A

    Time frame: Predose up to Day 24 postdose in Part A

  6. Total Number of Metabolites and Identification of Metabolites of LY3549492 in Part A

    Total number of metabolites and identification of metabolites of LY3549492

    Time frame: Predose up to Day 24 postdose in Part A

  7. PK: AUC of LY3549492, [14C]-LY3549492, and Total Radioactivity in Plasma in Part B

    AUC of LY3549492, \[14C\]-LY3549492, and total radioactivity in plasma in Part B

    Time frame: Predose up to Day 7 postdose in Part B

  8. PK: Cmax of LY3549492, [14C]-LY3549492, and Total Radioactivity in Plasma in Part B

    Cmax of LY3549492, \[14C\]-LY3549492, and total radioactivity in plasma in Part B

    Time frame: Predose up to Day 7 postdose in Part B

  9. Total Radioactivity Recovered in Urine and Feces in Part B

    Total radioactivity recovered in urine and feces in Part B

    Time frame: Predose up to Day 7 postdose in Part B

07

Study locations

1 site
  • Fortrea Clinical Research Unit
    Holbeck, Leeds LS11 9EH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Feb 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 8, 2024
StartActual
Jan 3, 2024
Primary completionActual
Feb 15, 2024
CompletionActual
Feb 15, 2024
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06194500
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Jan 3, 2024
Primary completion
Feb 15, 2024
Completion
Feb 15, 2024
Last update
Mar 28, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 : Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naperiglipron

Start the discussion